Zdrowie i gospodarka · 13/11/2023

FDA Clears COGENTIN (Benztropine Mesylate) Injection for Continued Approval

The US Food and Drug Administration (FDA) has ruled that COGENTIN (benztropine mesylate) Injection, 1 mg/1 mL, was not withdrawn from sale due to safety or effectiveness concerns. This decision means the FDA will not initiate withdrawal procedures for abbreviated new drug applications (ANDAs) referencing this product.